The downgrade from Outperform to Market Perform by a reputable analyst, along with a drastic reduction in the price target, is likely to negatively impact investor sentiment and the stock price of AN2 Therapeutics in the short term. Such a significant adjustment in both rating and price target suggests a reassessment of the company's future growth prospects or operational performance, which could lead to a decrease in stock price as investors adjust their expectations.